- Home
- QFIN vs ACAD Comparison
QFIN vs ACAD Comparison
Compare QFIN & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- ACAD
- Stock Information
- Founded
- QFIN 2016
- ACAD 1993
- Country
- QFIN China
- ACAD United States
- Employees
- QFIN N/A
- ACAD N/A
- Industry
- QFIN Finance: Consumer Services
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- QFIN Finance
- ACAD Health Care
- Exchange
- QFIN Nasdaq
- ACAD Nasdaq
- Market Cap
- QFIN 3.4B
- ACAD 3.5B
- IPO Year
- QFIN 2018
- ACAD 2004
- Fundamental
- Price
- QFIN $20.80
- ACAD $22.25
- Analyst Decision
- QFIN Strong Buy
- ACAD Buy
- Analyst Count
- QFIN 2
- ACAD 21
- Target Price
- QFIN $45.10
- ACAD $29.43
- AVG Volume (30 Days)
- QFIN 1.9M
- ACAD 2.0M
- Earning Date
- QFIN 11-18-2025
- ACAD 11-05-2025
- Dividend Yield
- QFIN 7.21%
- ACAD N/A
- EPS Growth
- QFIN 68.82
- ACAD 615.00
- EPS
- QFIN 7.06
- ACAD 1.33
- Revenue
- QFIN $2,618,582,596.00
- ACAD $1,018,885,000.00
- Revenue This Year
- QFIN $17.10
- ACAD $14.01
- Revenue Next Year
- QFIN $6.28
- ACAD $12.00
- P/E Ratio
- QFIN $2.99
- ACAD $17.00
- Revenue Growth
- QFIN 9.77
- ACAD 14.41
- 52 Week Low
- QFIN $20.45
- ACAD $13.40
- 52 Week High
- QFIN $48.94
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- QFIN 23.89
- ACAD 52.32
- Support Level
- QFIN $20.45
- ACAD $22.05
- Resistance Level
- QFIN $27.59
- ACAD $23.05
- Average True Range (ATR)
- QFIN 1.13
- ACAD 0.80
- MACD
- QFIN -0.50
- ACAD 0.29
- Stochastic Oscillator
- QFIN 4.65
- ACAD 76.30
About QFIN Qifu Technology Inc.
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.